Tianeptine Sulfate, ≥98%
You need to have an approved account to purchase this product.
TIANEPTINE SULFATE, ≥98%
Chemical Name: 7-[(3-Chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino] heptanoic acid hemisulfate monohydrate
Synonyms: Heptanoic acid, 7-((3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo(c,f)(1,2)thiazepin-11-yl)amino)-, sulfate, hydrate (2:1:2), Tianeptine hemisulfate monohydrate
CAS #: 1224690-84-9
Used in clinical trials for major depressive disorder (MDD), also studied for effects on asthma and irritable bowel syndrome (IBS).
Form: White powder
Molecular Formula: C21H25ClN2O4S •H2O.H2-(1/2)O4S;
Molecular Weight: 504.00
Solubility: Sparingly soluble in Water and DMSO
Precaution and Disclaimer:
This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.
|Melting Point:||129-131 °C|
|Synonyms:||Coaxil, Tianeptine Sodium, JICJBGPOMZQUBB-UHFFFAOYSA-N, Stablon, 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid|
|PubChem Substance ID:||45375836|
|Application:||Improved salt of Tianeptine, used in laboratory research related to major depressive disorder (MDD), also studied for effects on asthma and irritable bowel syndrome (IBS).|
|Solubility:||Sparingly soluble in water and DMSO|
|Storage:||Store in closed container at -20 °C in dark, dry conditions.|
|Stability:||Tianeptine sulfate is stable for at least four years when stored as above.|
Modes of Action:
One of the primary modes of action for Tianeptine is to increase serotonin (5-HT) uptake in the brain and in platelets. Unlike most tricyclic compounds, Tianeptine does not appear to be associated with decreases in cognitive performance or motor function. It appears to have activity on the glutamatergic system, which is hypothesized to be a novel antidepressant mechanism.
By increasing serotonin uptake, Tianeptine has an opposite mechanism to traditional SSRIs. Recent studies have examined the effects of Tianeptine within the framework of the neuroplasticity hypothesis of depression, in which it may have some activity. Recent research also shows that Tianeptine may interact with adenosine A1 receptors.
Furthermore, very recent research published in 2014 suggests that Tianeptine may act as an m -opioid receptor (MOR) agonist. Researchers used radioligand binding and cell-based functional assays to identify Tianeptine as an effective MOR agonist. It is also a full d-opioid agonist but at a much lower affinity. Tianeptine was ineffective at k-opioid receptor sites. The authors suggested activation of MOR or dual activation of MOR and DOR as the initial trigger for Tianeptine’s effects.
Further Scientific research:
Please note that this is an incomplete account of the scientific research on Tianeptine to date. We have made a humble attempt to convey some of the most relevant research on the subject to date, in a variety of applications. However, there is far too much research to condense in this space. For more research, please select a topic and search through the hundreds of journal articles published in PubMed.
In a review paper published in 2001, researchers found that Tianeptine was highly effective in a number of applications. The authors concluded that Tianeptine showed favorable antidepressant activity and was well tolerated throughout previous studies.
The researchers recorded an average dosage of around 25 – 50 mg/day. The paper also stated that the biochemical activity of Tianeptine was comparable to a number of classical antidepressant agents. Common adverse effects included nausea, constipation, gastrointestinal discomfort, headache, dizziness, and dream changes. Hepatoxicity was rare.
A second review, published in 1988, found similar results. The authors concluded that Tianeptine was an effective antidepressant agent for patients fulfilling the diagnostic criteria of the DSM III for depression. The paper indicated that Tianeptine also had efficacy on anxiety symptoms, the results of which had been confirmed in open long-term trials on elderly people.
The latest review available on PubMed, published in 2010, indicates that Tianeptine has marked activity in the glutamatergic system. The authors state that these results appear to be consistent with a growing body of research converging on the function of glutamate in neuroplasticity and depression.
In a 2015 study, researchers indicated that Tianeptine had no effects on the emotional categorization of cognition. Tianeptine-treated subjects scored lower on facial expression identification and had reduced positive affective memory, however, the authors did not state whether or not this was statistically significant.
Three separate double-blind, placebo-controlled studies examined the efficacy of Tianeptine in the treatment of major depressive episodes. The results were published in a 1997 paper. Two of the studies indicated Tianeptine to be an effective antidepressant agent when compared to both placebo and other agents. The third study had an overly high rate of placebo-responders and no conclusion could be made. The author suggested the need for a controlled study to determine the position of Tianeptine among other antidepressants.
A third study verified Tianeptine’s action on serotonin uptake. According to the authors, Tianeptine appears to reduce the hypothalamic-pituitary-adrenal response to stress and to reduce stress-related behavior and changes in cerebral morphology. It may have future application as an antidepressant and have efficacy for post-alcohol-withdrawal subjects. Apparent side effects from Tianeptine dosage included dry mouth, constipation, dizziness, drowsiness, and hypotension. However, these side effects appeared to occur more rarely than with other antidepressant agents that were measured.
In a 2004 study into the effects of Tianeptine on bronchial asthma, researchers emphasized the efficacy of Tianeptine on improving these symptoms. Its success was measured over a number of trials, including an open study that lasted for over 7 years and was conducted on over 25’000 asthmatic patients. The mechanism for this action is hypothesized to be due to its enhancement of serotonin uptake by platelets and serotonergic axons.
At least one case of fatal intoxication with Tianeptine was reported. In 2007, a 26-year-old-man was found dead in his bed with a suicide note next to his body. Tianeptine blood concentrations were found: blood 5.1 micro g/mL; urine 2.0 micro g/mL; liver 23 micro g/mL; stomach 22mg. He also had blood alcohol level of 0.53 g/L. The absence of any other suitable causes of death led to the death being ruled as caused by the suicidal ingestion of Tianeptine in combination with alcohol.
One case was reported of a patient who developed hepatitis after taking Tianeptine for 8 weeks. Discontinuing Tianeptine resulted in a complete recovery. The authors suggested that there may be the possibility of hypersensitivity and immuno-allergic mechanisms in hepatotoxicity with Tianeptine.
In 2015, a young adult man from Texas died after taking an acute large dose of Tianeptine. The company that he purchased it from sold it for household use and did not attach any warnings or instructions on how to take it. Please note that all NewMind chemical compounds are sold for research and laboratory purposes only and are strictly not for human consumption.
"We have moved away from studying human disease in humans … We all drank the Kool-Aid on that one, me included … The problem is that it hasn't worked, and its time we stopped dancing around the problem … We need to refocus and adapt new methodologies for use in humans to understand disease biology in humans," former NIH Director, Dr. Elias Zerhouni in the June 21, 2013, NIH Record.
While Newmind values the previous work and research of talented and dedicated scientists on various substances, we also value the principles of ethics towards which many of the world’s top scientists strive. There is already a large amount of data published on Tianeptine’s effects on rodents and small mammals, including toxicity studies on domestic household animals.
Research has shown that Tianeptine appears to differ from other antidepressant agents, offering an anxiolytic effect but without similarity to benzodiazepines. In nonhuman animal studies, Tianeptine was not found to impair spatial memory. Tianeptine was studied on cats and found to increase compartmental adaptation models in stress. Research data showed that Tianeptine increased the activity of the hippocampus and increased serotonin uptake in rat and human platelets. Data also showed that it decreases CRF and ACTH levels.
A 1988 study on the neurochemical profile of Tianeptine on nonhuman animals found that it differed significantly from other tricyclic and alternative antidepressant agents. Treatment of rat platelets and synaptosomes with Tianeptine increased serotonin uptake and did not inhibit MAO, MAOA or MAOB activity. Tianeptine did not bind to any of the following receptors, in vitro: alpha- and beta-adrenergic, dopamine, serotonin, imipramine, GABA, glutamate, benzodiazepine, muscarinic, histamine, Ca2+ channels.
Accidental or Intentional Ingestion or Administration of Quantities of Tianeptine Exceeding 100mg Can Result in Serious Toxicity or DEATH. Store Securely, and Handle with Maximum Caution using Appropriate Equipment!
-  TI Uzbay. (2008). Tianeptine: potential influences on neuroplasticity and novel pharmacological effects. Prog Neuropsychopharmacol Biol Psychiatry, 32(4):915-24.
-  M Gassaway, Rives ML, Kruegel AC, Javitch JA, Sames D. (2014). The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Translational Psychiatry, 4, e411.
-  Wagstaff AJ, Ormrod D, Spencer CM. (2004). Tianeptine: a review of its use in depressive disorders, CNS Drugs, 15(3):231-59.
-  Marey C, Kamoun M, Defrance R. (1988). Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. Clin Neuropharmacol, 11 Suppl 2:S74-82.
-  McEwen BS, Chattarji S, Diamond DM, et al. (2010). The neurobiological properties of Tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Molecular psychiatry, 15(3):237-249.
-  Cooper CM, Whiting DA, Cowen PJ, Harmer CJ. (2015). Tianeptine in an experimental medicine model of antidepressant action, J Psychopharmacol, 29(5):582-90.
-  D Ginestet. (1997). Efficacy of tianeptine in major depressive disorders with or without melancholia. Eur Neuropsychopharmacol, 7 Suppl 3:S341-5.
-  Wilde MI, Benfield P. (1995). Tianeptine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs, 49(3):411-39.
-  Lechin F, vd Dijs B, Lechin AE. (2004). Treatment of bronchial asthma with tianeptine. Methods Find Exp Clin Pharmacol, 26(9):697-701.
-  Proenca P, Teixeira H, Pinheiro J, Monsanto PV, Vieira DN. (2007). Fatal intoxication with tianeptine (Stablon), Forensic Sci Int, 6;170(2-3):200-3.
-  Le Brizquir Y, Larrey D, Blanc P, Pageaux GP, Michel H. (1994). Tianeptine--an instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol, 21(5):771-3.
-  Suayan J. (2016). Harris County couple alleges lack of warnings on antidepressant led to son's death. SE Texas Record. Available online from https://setexasrecord.com/stories/511049463-harris-county-couple-alleges-lack-of-warnings-on-antidepressant-led-to-son-s-death [Accessed Jul 5, 2018]
-  Capaldo T. (2014). Animal Data Is Not Reliable for Human Health Research (Op-Ed), NEAVS, Livescience.com. Available online from https://www.livescience.com/46147-animal-data-unreliable-for-humans.html [Accessed Jul 5, 2018].
-  Kamoun A, et al. (1989). [Tianeptine, an uncommon psychotropic drug] (Article in Russian). Encephale, 15(4):419-22.
-  Kato G, Weitsch AF. (1988). Neurochemical profile of tianeptine, a new antidepressant drug. Clin Neuropharmacol, 11 Suppl 2:S43-50.
Precaution and Disclaimer:
[Tianeptine Sulfate Q1 2018] Tianeptine.Sulfate.18012702.pdf
[Tianeptine Sulfate Q4 2017] Tianeptine.Sulfate.17120201.pdf
[Tianeptine Sulfate Q3 2017] Tianeptine.Sulfate.17081702.pdf
[Tianeptine Sulfate Q3 2017] Tianeptine.Sulfate.17070301.pdf
[Tianeptine Sulfate Q3 2017] Tianeptine.Sulfate.17052001.pdf
[Tianeptine Sulfate Q2 2017] Tianeptine.Sulfate.17060101.pdf
[Tianeptine Sulfate Q2 2017] Tianeptine.Sulfate.17050201.pdf
[Tianeptine Sulfate Q4 2016] Tianeptine.Sulfate.201611022.pdf
[Tianeptine Sulfate Q3 2016] Tianeptine.Sulfate.2016081911.pdf